Switching on the cell's own protein shredders restored mitochondrial function — in lab-grown human cells
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
In cultured human cells, a small molecule called BD2 released the brake on the CUL2FEM1B protein-degradation enzyme, restoring mitochondrial respiration and preventing neuron death in cell models of COX deficiency, and matching an approved drug in Friedreich's ataxia cell models (Science, October 29, 2026). The approach, stimulated protein degradation, is cell-culture evidence only — no animal or human testing has been reported.
Targeted protein degradation taught drug hunters to aim the cell's shredder at one protein at a time. This study aims it at the brake pedal instead — and in dishes of human neurons, mitochondria that could not breathe started breathing again.
How does stimulated protein degradation work?
E3 ubiquitin ligases tag proteins for destruction. CUL2FEM1B is a stress-responsive ligase that protects mitochondrial function by clearing proteins such as FNIP1 that obstruct the TOM import channels mitochondria use to take in proteins — clearance that supports assembly of complex IV of the electron transport chain. BEX proteins inhibit the ligase by occupying its substrate-binding pocket without being degraded themselves. Chandrasekhar and colleagues screened about 120,000 compounds in paired assays for molecules that displace BEX while leaving substrate binding intact. The hit, BD1, blocked BEX3 binding at an IC50 near 2 micromolar; its cell-active analogue BD2 displaced all detectable BEX proteins, lowered a mitochondrial FNIP1 reporter with a cellular IC50 of 1.1 micromolar, increased mitochondrial import, complex IV subunits and respiration — and every effect vanished when FEM1B was deleted or its pocket mutated, tying the result to the intended target.
What happened in the disease models?
The team tested SPD in cellular models of cytochrome c oxidase deficiency, a group of mitochondrial disorders of the electron transport chain. In neurons derived from induced pluripotent stem cells, the defects reduced complex IV levels and increased cell death; BD2 restored complex IV subunit levels, restored the 30-to-40-percent respiratory capacity the models had lost, and prevented neuronal death. In frataxin-depleted cell models of Friedreich's ataxia, BD2's benefit matched optimal dosing of omaveloxolone, the approved KEAP1-targeting drug for that disease. A Perspective published alongside the paper (Ramanujan Hegde, MRC Laboratory of Molecular Biology) notes the strategy could in principle be extended to other quality-control ligases such as Parkin, whose activation clears dysfunctional mitochondria and is of interest in Parkinson's disease.
What are the limits of this result?
They are substantial and the coverage of this paper has been unusually candid about them. All data come from cultured cells (293T, C2C12 and iPSC-derived neurons) — there is no animal pharmacokinetics, no animal efficacy, and no human data of any kind. BD2 was used at concentrations up to 100 micromolar in some assays, so potency needs optimization before it resembles a drug. It also failed to correct certain defects in other electron transport chain complexes, which means CUL2FEM1B activation is likely to help only where the disease mechanism runs through the pathways this ligase controls. And BD2 is not a pure agonist: it occupies the same pocket used by some substrates and stabilized a CDK5R1 reporter at similar concentrations. The honest summary is a new, validated drug-discovery strategy with a striking first demonstration — in dishes.
Frequently asked questions
What is stimulated protein degradation?
A drug strategy in which a small molecule activates one of the cell's own quality-control E3 ligases so it degrades several of its natural substrate proteins at once — the opposite of targeted degradation approaches that aim the machinery at a single chosen protein.
What did BD2 do to mitochondria?
In cultured cells, BD2 displaced the BEX proteins that restrain the CUL2FEM1B ligase, increasing mitochondrial protein import, complex IV subunits and respiration. In COX-deficiency cell models it restored respiratory capacity and prevented neuron death; in Friedreich's ataxia cell models it matched the approved drug omaveloxolone.
Is BD2 a treatment for mitochondrial disease?
No. Every result is in cultured cells. There is no animal or human testing, the compound's potency needs optimization, and it did not rescue every mitochondrial defect tested.
Where the evidence stands
- Established: E3 ubiquitin ligases tag proteins for degradation; CUL2FEM1B is a stress-responsive ligase that supports mitochondrial protein import by degrading import-blocking substrates such as FNIP1; and BEX proteins restrain it by occupying its substrate pocket.
- Preliminary: In cultured cells (Science, Oct 29, 2026; DOI 10.1126/science.aed2525), the BEX-displacing compound BD2 increased mitochondrial import, complex IV subunits and respiration without triggering reactive oxygen species, restored respiratory capacity cut 30–40% in COX-deficiency cell models, prevented death of iPSC-derived neurons, and matched omaveloxolone in frataxin-depleted Friedreich's ataxia models. BD2 did not rescue defects in other electron transport chain complexes.
- Absent: Animal pharmacokinetics or efficacy, any human data, and any evidence that BD2 or an optimized successor can be dosed safely in a living organism.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.